COVID-19
Conditions
Brief summary
The main objective of this research is to identify and characterize the different molecular variants of SARS-CoV-2, emerging and / or circulating in several countries of Sub-Saharan Africa (Burkina Faso, Côte d'Ivoire, Gabon, Mali, Chad and Republic of Congo) and determine their role in the evolution of the pandemic.
Detailed description
The main objective of this research is to identify and characterize the different molecular variants of SARS-CoV-2, emerging and / or circulating in several countries of Sub-Saharan Africa (Burkina Faso, Côte d'Ivoire, Gabon, Mali, Chad and Republic of Congo) and determine their role in the evolution of the pandemic. The research will combine retrospective and prospective approaches to determine the evolutionary dynamics of the virus since the start of the pandemic. It is planned to sequence the entire Spike protein gene for 1550 viruses and make 300 entire genomes. This work will be supplemented by antibody seroneutralization and respiratory transcriptomics tests, in order to estimate the immuno-virological response of the COVID-19 disease associated with the identified SARS-CoV-2 variants.
Interventions
DIAGNOSTIC_TESTRT PCR
Characterize the different molecular variants of SARS-CoV-2, determine the escape potential of the new variants from neutralization by monoclonal antibodies and currently available vaccines and characterization of the mRNAs expressed in infected persons
Sponsors
Institut de Recherche pour le Developpement
Institut National de la Santé Et de la Recherche Médicale, France
ANRS, Emerging Infectious Diseases
Study design
Observational model
CASE_ONLY
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Major subject (cf. country) * Presenting for a SARS-COV-2 diagnosis, whether symptomatic or not * Not objecting to participating in the research
Exclusion criteria
* NA
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of SARS-CoV-2 sequences generated partially and in whole genome | Through study completion, an average of 1 year. | This outcome represent our main gaol and will include sequences that were partially generated in the Spike proteine and full genomes as well. Our current target is 1550 sequences. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of individuals tested positive for COVID-19 | Up to six months | This outcome will be focused on the number of persons that will be tested positive for COVID-19 throughout the study, using SARS-CoV-2 rapid antigen tests. We planned to screen 12000 individuals overall in the six participating countries. |
| Number of new SARS-CoV-2 variants identify | Through study completion, an average of 1 year. | This outcome represents the number of new viruses that are identified at the end of the study and have not been reported previously. |
Countries
Burkina Faso, Chad, Côte d’Ivoire, Gabon, Mali, Republic of the Congo
Outcome results
None listed